Precigen (PGEN) drew fresh attention after reporting updated long-term data for PAPZIMEOS in adult recurrent respiratory papillomatosis, alongside full FDA approval and seven-year market exclusivity for the therapy.

The recent PAPZIMEOS approval and durable response data arrived alongside sharp price moves, with the share price at $4.53 after a 1-day share price return of 16.45% and a 1-year total shareholder return of about 3x. This suggests strong positive momentum built over the past year.

If this kind of biotech progress has your attention, it could be a good moment to scan other healthcare and treatment-focused companies through our 40 healthcare AI stocks

With PAPZIMEOS now approved, seven-year exclusivity in place, and the stock up about 3x in a year, the key question is whether Precigen is still undervalued or if the market is already accounting for potential future growth.

DCF valuation: what the SWS model suggests at $4.53

The SWS DCF model currently estimates Precigen's future cash flow value at $23.88 per share, compared with the last close of $4.53. This indicates a large gap between price and modeled value.

The DCF approach projects future cash flows, then discounts them back to today using a required rate of return, so distant cash flows count less than near term ones. That framework can be useful for a discovery and clinical stage biopharmaceutical company like Precigen, where near term reported earnings are negative but expectations are heavily tied to potential future therapies and platform economics.

For a stock that is still loss making, a cash flow based lens can sometimes highlight how much optimism is embedded in assumptions about future revenue growth, margin progression, and the timing of a possible move into profitability. It also helps explain why the model can sit far above the market price when reported net income remains deeply negative.

Result: DCF Fair value of $23.88 (UNDERVALUED)

However, there are still clear pressure points, including ongoing net losses of about US$383.4 million and a market value of roughly US$1.6b that could reset quickly if sentiment shifts.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another angle on valuation: check the P/B signal

That DCF gap looks large, but the P/B ratio points in the opposite direction. Precigen trades at a P/B of 79.8x, compared with 2.3x for the US Biotechs industry and 6x for peers, which suggests the stock is priced well above what many similar companies trade at.

For you, that kind of premium can signal confidence in future outcomes or simply valuation risk if expectations cool. The P/B ratio also sits far away from the fair ratio our model suggests the market could move toward over time. Which signal do you trust more: the cash flow story or the balance sheet premium?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Precigen for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given how mixed the signals are, with a big DCF gap on one side and a rich P/B on the other, it makes sense to look closely at both the upside potential and what could go wrong, and then decide where you stand. To help frame that balance, start with the 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If this kind of detailed look at Precigen has sharpened your thinking, do not stop here, your next strong idea might be sitting just outside your current watchlist.

• Target opportunities that combine quality with a potential price gap by scanning the 46 high quality undervalued stocks.
• Prioritize resilience and sleep a little easier at night by focusing on companies in the 67 resilient stocks with low risk scores.
• Get ahead of the crowd by searching for potential future standouts with the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.